It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.
US politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data used in the approval of its $2.1 million spinal muscular atrophy (SMA) gene therapy Zolge
After all the anticipation, Novartis has the FDA approval it has been seeking for Zolgensma, its gene therapy for spinal muscular atrophy, and has priced it at the low end of expectations.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
